Renexxion - Ireland
  • Home
  • Company
    • Our Vision
    • Our Leadership Team
  • ​Naronapride (ATI-7505)
    • About Naronapride (ATI-7505)
    • Mechanism of Action
    • Development Status
    • Chemistry and Manufacturing
    • Regulatory Developments
  • Knowledge Centre
    • Gastrointestinal Dysmotility in Cystic Fibrosis (CF)
    • Gastroparesis
    • Chronic Idiopathic Constipation
    • Irritable Bowel Syndrome
    • ​GERD
    • Functional Dyspepsia
  • News
    • Press >
      • Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Initiation of Phase II Study of naronapride in patients with gastroparesis
      • Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients
      • Gastrointestinal Biotech Company Renexxion Ireland Announces $100M Investment Commitment
      • Renexxion Ireland Announces Issuance of a New US Patent covering Naronapride, a Clinical Stage Potential Best-in-Class Prokinetic Agent for Gastrointestinal Disorders
      • Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH
  • Contact

Over 100 million patients globally need a safe and
​effective pan-GI pro-kinetic treatment
.

Learn more

Renexxion Ireland Innovation

Renexxion Ireland Limited is a pharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (GI) disorders with its pipeline in a pill: Naronapride.

​Naronapride is a late-development stage, pan-GI prokinetic. It is a highly selective 5HT-4 agonist and D2 antagonist, both validated targets for GI motility. Naronapride has been designed to be minimally absorbed, avoiding systemic effects and acting locally in the gut lumen.

It is estimated that at least 16% of people worldwide are affected by GI-related  disorders. Currently approved therapies do not completely address the high therapeutic need. Naronapride has the potential to address the major GI indications associated with dysmotility including gastroparesis, chronic idiopathic constipation (CIC), irritable bowel syndrome- constipation (IBS-C), gastro-esophageal reflux disease (GERD) and functional dyspepsia (FD).

Naronapride is being developed for GI dysmotility in Cystic Fibrosis, a respiratory disease with significant GI morbidity. There are no other prokinetics in active development for GI dysmotility in CF, making Naronapride a potential best-in-class.

Learn more
Privacy Policy & Terms of Use
Copyright RENEXXION IRELAND LTD  2023.  All rights reserved.
  • Home
  • Company
    • Our Vision
    • Our Leadership Team
  • ​Naronapride (ATI-7505)
    • About Naronapride (ATI-7505)
    • Mechanism of Action
    • Development Status
    • Chemistry and Manufacturing
    • Regulatory Developments
  • Knowledge Centre
    • Gastrointestinal Dysmotility in Cystic Fibrosis (CF)
    • Gastroparesis
    • Chronic Idiopathic Constipation
    • Irritable Bowel Syndrome
    • ​GERD
    • Functional Dyspepsia
  • News
    • Press >
      • Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Initiation of Phase II Study of naronapride in patients with gastroparesis
      • Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients
      • Gastrointestinal Biotech Company Renexxion Ireland Announces $100M Investment Commitment
      • Renexxion Ireland Announces Issuance of a New US Patent covering Naronapride, a Clinical Stage Potential Best-in-Class Prokinetic Agent for Gastrointestinal Disorders
      • Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH
  • Contact